Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Remaining Life Expectancy With and Without Polypharmacy: A Register-Based Study of Swedes Aged 65 Years and Older
Stockholms universitet, Samhällsvetenskapliga fakulteten, Centrum för forskning om äldre och åldrande (ARC), (tills m KI). University of Southern Denmark, Denmark.
Stockholms universitet, Samhällsvetenskapliga fakulteten, Centrum för forskning om äldre och åldrande (ARC), (tills m KI).
Antal upphovsmän: 42016 (Engelska)Ingår i: Journal of the American Medical Directors Association, ISSN 1525-8610, E-ISSN 1538-9375, Vol. 17, nr 1, s. 31-35Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Objectives: To investigate the remaining life expectancy with and without polypharmacy for Swedish women and men aged 65 years and older. Design: Age-specific prevalence of polypharmacy from the nationwide Swedish Prescribed Drug Register (SPDR) combined with life tables from Statistics Sweden was used to calculate the survival function and remaining life expectancy with and without polypharmacy according to the Sullivan method. Setting: Nationwide register-based study. Participants: A total of 1,347,564 individuals aged 65 years and older who had been prescribed and dispensed a drug from July 1 to September 30, 2008. Measurements: Polypharmacy was defined as the concurrent use of 5 or more drugs. Results: At age 65 years, approximately 8 years of the 20 remaining years of life (41%) can be expected to be lived with polypharmacy. More than half of the remaining life expectancy will be spent with polypharmacy after the age of 75 years. Women had a longer life expectancy, but also lived more years with polypharmacy than men. Discussion: Older women and men spend a considerable proportion of their lives with polypharmacy. Conclusion: Given the negative health outcomes associated with polypharmacy, efforts should be made to reduce the number of years older adults spend with polypharmacy to minimize the risk of unwanted consequences.

Ort, förlag, år, upplaga, sidor
2016. Vol. 17, nr 1, s. 31-35
Nyckelord [en]
Polypharmacy, aged, life expectancy, sex difference, drug use
Nationell ämneskategori
Geriatrik Gerontologi, medicinsk/hälsovetenskaplig inriktning
Identifikatorer
URN: urn:nbn:se:su:diva-126194DOI: 10.1016/j.jamda.2015.07.015ISI: 000366756400009PubMedID: 26341036OAI: oai:DiVA.org:su-126194DiVA, id: diva2:898540
Tillgänglig från: 2016-01-28 Skapad: 2016-01-26 Senast uppdaterad: 2018-01-10Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed
Av organisationen
Centrum för forskning om äldre och åldrande (ARC), (tills m KI)
I samma tidskrift
Journal of the American Medical Directors Association
GeriatrikGerontologi, medicinsk/hälsovetenskaplig inriktning

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 31 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf